U.S. patent application number 11/349537 was filed with the patent office on 2006-08-31 for abuse-proofed dosage form.
Invention is credited to Elisabeth Arkenau-Maric, Johannes Bartholomaus, Heinrich Kugelmann.
Application Number | 20060193782 11/349537 |
Document ID | / |
Family ID | 34112032 |
Filed Date | 2006-08-31 |
United States Patent
Application |
20060193782 |
Kind Code |
A1 |
Bartholomaus; Johannes ; et
al. |
August 31, 2006 |
Abuse-proofed dosage form
Abstract
The invention relates to a form of administration which is
secured against misuse and which is thermoformed without extrusion,
including at least one synthetic or natural polymer having a
resistance to breaking of at least 500 N in addition to one or
several active ingredients with a misuse potential and, optionally
physiologically compatible auxiliary substances. The invention also
relates to a method for the production thereof.
Inventors: |
Bartholomaus; Johannes;
(Aachen, DE) ; Kugelmann; Heinrich; (Aachen,
DE) ; Arkenau-Maric; Elisabeth; (Koln, DE) |
Correspondence
Address: |
PERMAN & GREEN
425 POST ROAD
FAIRFIELD
CT
06824
US
|
Family ID: |
34112032 |
Appl. No.: |
11/349537 |
Filed: |
February 6, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
PCT/EP04/08793 |
Aug 5, 2004 |
|
|
|
11349537 |
Feb 6, 2006 |
|
|
|
Current U.S.
Class: |
424/10.1 |
Current CPC
Class: |
A61K 9/2027 20130101;
A61P 25/22 20180101; A61K 31/5513 20130101; A61K 9/2095 20130101;
A61K 47/10 20130101; A61K 9/20 20130101; A61P 25/04 20180101; A61K
9/2054 20130101; A61P 25/00 20180101; A61K 31/515 20130101; A61K
9/2031 20130101; A61K 31/485 20130101; A61K 9/0053 20130101; A61K
9/2013 20130101; A61P 25/30 20180101; A61K 9/205 20130101; A61K
9/2068 20130101; A61K 31/135 20130101 |
Class at
Publication: |
424/010.1 |
International
Class: |
A61K 49/00 20060101
A61K049/00 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 6, 2003 |
DE |
103 36 400.5 |
Claims
1. An abuse-proofed dosage form thermoformed without extrusion,
characterised in that, in addition to one or more active
ingredients with abuse potential (A) optionally together with
physiologically acceptable auxiliary substances (B), it contains at
least one synthetic or natural polymer (C) and optionally at least
one wax (D), wherein component (C) and the optionally present
component (D) exhibit a breaking strength of at least 500 N.
2. A dosage form according to claim 1, characterised in that it is
in the form of a tablet.
3. A dosage form according to claim 1, characterised in that it is
in multiparticulate form, preferably in the form of microtablets,
micropellets, granules, spheroids, beads or pellets, optionally
pressed into tablets or packaged in capsules.
4. A dosage form according to claim 1, characterised in that it
contains as polymer (C) at least one polymer selected from the
group comprising polyethylene oxide, polymethylene oxide,
polypropylene oxide, polyethylene, polypropylene, polyvinyl
chloride, polycarbonate, polystyrene, polyacrylate, copolymers and
the mixtures thereof, preferably polyethylene oxide.
5. A dosage form according to claim 1, characterised in that the
polyethylene oxide (C) has a molecular weight of at least 0.5
million.
6. A dosage according to claim 5, characterised in that the
molecular weight of the polyethylene oxide (C) is at least 1
million.
7. A dosage form according to claim 6, characterised in that the
molecular weight of the polyethylene oxide (C) is 1-15 million.
8. A dosage form according to claim 1, characterised in that it
contains as the wax (D) at least one natural, semi-synthetic or
synthetic wax with a softening point of at least 60.degree. C.
9. A dosage form according to claim 8, characterised in that the
wax (D) is carnauba wax or beeswax.
10. A dosage form according to claim 1, characterised in that the
component(s) (C) and optionally (D) is/are present in quantities
such that the dosage form has a breaking strength of at least 500
N.
11. A dosage form according to claim 1, characterised in that the
active ingredient (A) is at least one active ingredient selected
from the group comprising opioids, tranquillisers, stimulants,
barbiturates and further narcotics.
12. A dosage form according to claim 1 characterised in that it
additionally comprises at least one of the following components
a)-f): (a) at least one substance which irritates the nasal
passages and/or pharynx, (b) at least one viscosity-increasing
agent, which, with the assistance of a necessary minimum quantity
of an aqueous liquid, forms a gel with the extract obtained from
the dosage form, which gel preferably remains visually
distinguishable when introduced into a further quantity of an
aqueous liquid, (c) at least one antagonist for the active
ingredient or active ingredients with abuse potential (d) at least
one emetic, (e) at least one dye as an aversive agent, (f) at least
one bitter substance.
13. A dosage form according to claim 12, characterised in that the
component (a) irritant substance causes burning, itching, an urge
to sneeze, increased formation of secretions or a combination of at
least two of these stimuli.
14. A dosage form according to claim 11, characterised in that the
component (a) irritant substance is based on one or more
constituents of at least one hot substance drug.
15. A dosage form according to claim 14, characterised in that the
hot substance drug is at least one drug selected from the group
comprising Allii sativi bulbus (garlic), Asari rhizoma cum herba
(Asarum root and leaves), Calami rhizoma (calamus root), Capsici
fructus (capsicum), Capsici fructus acer (cayenne pepper), Curcumae
longae rhizoma (turmeric root), Curcumae xanthorrhizae rhizoma
(Javanese turmeric root), Galangae rhizoma (galangal root),
Myristicae semen (nutmeg), Piperis nigri fructus (pepper), Sinapis
albae semen (white mustard seed), Sinapis nigri semen (black
mustard seed), Zedoariae rhizoma (zedoary root) and Zingiberis
rhizoma (ginger root), particularly preferably at least one drug
selected from the group comprising Capsici fructus (capsicum),
Capsici fructus acer (cayenne pepper) and Piperis nigri fructus
(pepper).
16. A dosage form according to claim 14, characterised in that the
constituent of the hot substance drug is an o-methoxy(methyl)phenol
compound, an acid amide compound, a mustard oil or a sulfide
compound or is derived from such a compound.
17. A dosage form according to claim 14, characterised in that the
constituent of the hot substance drug is at least one constituent
selected from the group comprising myristicin, elemicin,
isoeugenol, .beta.-asarone, safrole, gingerols, xanthorrhizol,
capsaicinoids, preferably capsaicin, piperine, preferably
trans-piperine, glucosinolates, preferably based on non-volatile
mustard oils, particularly preferably based on p-hydroxybenzyl
mustard oil, methylmercapto mustard oil or methylsulfonyl mustard
oil, and a compound derived from these constituents.
18. A dosage form according to claim 12, characterised in that
component (b) is at least one viscosity-increasing agent selected
from the group comprising microcrystalline cellulose with 11 wt. %
carboxymethylcellulose sodium (Avicel.RTM. RC 591),
carboxymethylcellulose sodium (Blanose.RTM., CMC-Na C300P.RTM.,
Frimulsion BLC-5.RTM., Tylose C300 P.RTM.), polyacrylic acid
(Carbopol.RTM. 980 NF, Carbopol.RTM. 981), locust bean flour
(Cesagum.RTM. LA-200, Cesagum.RTM. LID/150, Cesagum.RTM. LN-1),
pectins from citrus fruit or apples (Cesapectin.RTM. HM Medium
Rapid Set), waxy maize starch (C*Gel 04201.RTM.), sodium alginate
(Frimulsion ALG (E401).RTM.), guar flour (Frimulsion BM.RTM.,
Polygum 26/1-75.RTM.), iota carrageen (Frimulsion D021.RTM.),
karaya gum, gellan gum (Kelcogel F.RTM., Kelcogel LT100.RTM.),
galactomannan (Meyprogat 150.RTM.), tara bean flour (Polygum
43/1.RTM.), propylene glycol alginate (Protanal-Ester SD-LB.RTM.),
apple pectin, sodium hyaluronate, tragacanth, tara gum (Vidogum SP
200.RTM.), fermented polysaccharide welan gum (K1A96), xanthan gum
(Xantural 180.RTM.).
19. A dosage form according to claim 12, characterised in that
component (c) is at least one opioid antagonist selected from the
group comprising naloxone, naltrexone, nalmefene, nalid, nalmexone,
nalorphine, naluphine and a corresponding physiologically
acceptable compound, in particular a base, a salt or solvate.
20. A dosage form according to claim 12, characterised in that the
component (c) used is at least one neuroleptic as a stimulant
antagonist, preferably selected from the group comprising
haloperidol, promethazine, fluphenazine, perphenazine,
levomepromazine, thioridazine, perazine, chlorpromazine,
chlorprothixine, zuclopentixol, flupentixol, prothipendyl,
zotepine, benperidol, pipamperone, melperone and bromperidol.
21. A dosage form according to claim 12, characterised in that the
component (d) emetic is based on one or more constituents of
ipecacuanha (ipecac) root, preferably on the constituent emetine,
and/or is apomorphine.
22. A dosage form according to claim 12, characterised in that
component (e) is at least one physiologically acceptable dye.
23. A dosage form according to claim 12, characterised in that
component (f) is at least one bitter substance selected from the
group comprising aromatic oils, preferably peppermint oil,
eucalyptus oil, bitter almond oil, menthol and mixtures thereof,
fruit aroma substances, preferably from lemons, oranges, limes,
grapefruit and mixtures thereof comprising at least 2 components,
denatonium benzoate and mixtures thereof comprising at least 2
components.
24. A dosage form according to claim 12 characterised in that the
active ingredient or active ingredients (A) is/are spatially
separated from component (c) and/or (d) and/or (f), preferably
without direct contact, wherein the active ingredient or active
ingredients (A) is/are preferably present in at least one subunit
(X) and components (c) and/or (d) and/or (f) is/are present in at
least one subunit (Y), and, when the dosage form is correctly
administered, components (c) and/or (d) and/or (f) from subunit (Y)
do not exert their effect in the body and/or on taking.
25. A dosage form according to claim 1, characterised in that it
contains at least one active ingredient at least partially in
controlled release form.
26. A dosage form according to claim 25, characterised in that each
of the active ingredients with abuse potential (A) is present in a
controlled release matrix.
27. A dosage form according to claim 26, characterised in that
component (C) and/or the optionally present component (D) also
serve as a controlled release matrix material.
28. A process for the production of a dosage form according to
claim 1, characterised in that, without using an extruder,
components (A), (B), (C) and the optionally present component (D)
are mixed and the optionally present components (a) to (f) are
co-mixed or, if necessary, are separated mixed with addition of
component (C) and optionally (D) and the resultant mixture or
mixtures, optionally after granulation, is/are shaped by
application of force to yield the dosage form with preceding or
simultaneous exposure to heat.
29. A process according to claim 28, characterised in that
granulation is performed by melt granulation or wet
granulation.
30. A dosage form according to claim 1 obtainable by a process
according to claim 28.
Description
[0001] The present invention relates to an abuse-proofed dosage
form thermoformed without extrusion containing, in addition to one
or more active ingredients with abuse potential (A) optionally
together with physiologically acceptable auxiliary substances (B),
at least one synthetic or natural polymer (C) and optionally at
least one wax (D), wherein component (C) and the optionally present
component (D) in each case exhibits a breaking strength of at least
500 N, and to a process for the production of the dosage form
according to the invention.
[0002] Many pharmaceutical active ingredients, in addition to
having excellent activity in their appropriate application, also
have abuse potential, i.e. they can be used by an abuser to bring
about effects other than those intended. Opiates, for example,
which are highly active in combating severe to very severe pain,
are frequently used by abusers to induce a state of narcosis or
euphoria.
[0003] In order to make abuse possible, the corresponding dosage
forms, such as tablets or capsules are comminuted, for example
ground in a mortar, by the abuser, the active ingredient is
extracted from the resultant powder using a preferably aqueous
liquid and the resultant solution, optionally after being filtered
through cotton wool or cellulose wadding, is administered
parenterally, in particular intravenously. An additional phenomenon
of this kind of administration, in comparison with abusive oral
administration, is a further accelerated increase in active
ingredient levels giving the abuser the desired effect, namely the
"kick" or "rush". This kick is also obtained if the powdered dosage
form is administered nasally, i.e. is sniffed. Since
controlled-release dosage forms containing active ingredients with
abuse potential do not give rise to the kick desired by the abuser
when taken orally even in abusively high quantities, such dosage
forms are also comminuted and extracted in order to be abused.
[0004] U.S. Pat. No. 4,070,494 proposed adding a swellable agent to
the dosage form in order to prevent abuse. When water is added to
extract the active ingredient, this agent swells and ensures that
the filtrate separated from the gel contains only a small quantity
of active ingredient.
[0005] The multilayer tablet disclosed in WO 95/20947 is based on a
similar approach to preventing parenteral abuse, said tablet
containing the active ingredient with abuse potential and at least
one gel former, each in different layers.
[0006] WO 03/015531 A2 discloses another approach to preventing
parenteral abuse. A dosage form containing an analgesic opioid and
a dye as an aversive agent is described therein. The colour
released by tampering with the dosage form is intended to
discourage the abuser from using the dosage form which has been
tampered with.
[0007] Another known option for complicating abuse involves adding
antagonists to the active ingredients to the dosage form, for
example naloxone or naltexone in the case of opioids, or compounds
which cause a physiological defence response, such as for example
ipecacuanha (ipecac) root.
[0008] However, since in most cases of abuse it is still necessary
to pulverise the dosage form comprising an active ingredient
suitable for abuse, it was the object of the present invention to
complicate or prevent the pulverisation preceding abuse of the
dosage form using the means conventionally available to a potential
abuser and accordingly to provide a dosage form for active
ingredients with abuse potential which ensures the desired
therapeutic effect when correctly administered, but from which the
active ingredients cannot be converted into a form suitable for
abuse simply by pulverisation.
[0009] Said object has been achieved by the provision of the
abuse-proofed dosage form thermoformed without extrusion according
to the invention which contains, in addition to one or more active
ingredients with abuse potential (A), at least one synthetic or
natural polymer (C) and optionally at least one wax (D), wherein
component (C) and the optionally present component (D) in each case
exhibits a breaking strength of at least 500 N.
[0010] The use of polymers having the stated minimum breaking
strength (measured as stated in the application), preferably in
quantities such that the dosage form also exhibits such a minimum
breaking strength of at least 500 N, means that pulverisation of
the dosage form is considerably more difficult using conventional
means, so considerably complicating or preventing the subsequent
abuse.
[0011] If comminution is inadequate, parenteral, in particular
intravenous, administration cannot be performed safely or
extraction of the active ingredient therefrom takes too long for
the abuser or there is no "kick" when taken orally, as release is
not instantaneous.
[0012] According to the invention, comminution is taken to mean
pulverisation of the dosage form with conventional means which are
available to an abuser, such as for example a mortar and pestle, a
hammer, a mallet or other usual means for pulverisation by
application of force.
[0013] The dosage form according to the invention is thus suitable
for preventing parenteral, nasal and/or oral abuse of active
ingredients, preferably of pharmaceutical active ingredients with
abuse potential.
[0014] Pharmaceutical active ingredients with abuse potential are
known to the person skilled in the art, as are the quantities
thereof to be used and processes for the production thereof, and
may be present in the dosage form according to the invention as
such, in the form of the corresponding derivatives thereof, in
particular esters or ethers, or in each case in the form of
corresponding physiologically acceptable compounds, in particular
in the form of the salts or solvates thereof, as racemates or
stereoisomers. The dosage form according to the invention is also
suitable for the administration of two or more pharmaceutical
active ingredients. The dosage form preferably contains only one
specific active ingredient.
[0015] The dosage form according to the invention is in particular
suitable for preventing abuse of a pharmaceutical active ingredient
selected from the group comprising opioids, tranquillisers,
preferably benzodiazepines, barbiturates, stimulants and other
narcotics.
[0016] The dosage form according to the invention is very
particularly suitable for preventing abuse of an opioid,
tranquilliser or another narcotic selected from the group
comprising
N-{1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-methoxymethyl-4-piperid-
yl}propionanilide (alfentanil), 5,5-diallylbarbituric acid
(allobarbital), allylprodine, alphaprodine,
8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]-benzodiazepine
(alprazolam), 2-diethylaminopropiophenone (amfepramone),
(.+-.)-a-methyl-phenethylamine (amphetamine),
2-(a-methylphenethylamino)-2-phenylacetonitrile (amphetaminil),
5-ethyl-5-isopentylbarbituric acid (amobarbital), anileridine,
apocodeine, 5,5-diethylbarbituric acid (barbital), benzylmorphine,
bezitramide, 7-bromo-5-(2-pyridyl)-1H-1,4-benzodiazepine-2(3H)-one
(bromazepam),
2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo-[4,3--
a][1,4]diazepine (brotizolam),
17-cyclopropylmethyl-4,5a-epoxy-7a[(S)-1-hydroxy-1,2,2-trimethyl-propyl]--
6-methoxy-6,14-endo-ethanomorphinan-3-ol (buprenorphine),
5-butyl-5-ethylbarbituric acid (butobarbital), butorphanol,
(7-chloro-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl)d-
imethylcarbamate (camazepam), (1S,2S)-2-amino-1-phenyl-1-propanol
(cathine/D-norpseudoephedrine),
7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-ylamine 4-oxide
(chlordiazepoxide),
7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione
(clobazam),
5-(2-chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one
(clonazepam), clonitazene,
7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic
acid (clorazepate),
5-(2-chlorophenyl)-7-ethyl-1-methyl-1H-thieno[2,3-e][1,4]diazepin-2(3H)-o-
ne (clotiazepam),
10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydrooxazolo-[3,2-d][1,4]be-
nzodiazepin-6(5H)-one (cloxazolam),
(-)-methyl-[3.beta.-benzoyloxy-2.beta.(1aH,5aH)-tropancarboxylate](cocain-
e), 4,5a-epoxy-3-methoxy-17-methyl-7-morphinan-6a-ol (codeine),
5-(1-cyclohexenyl)-5-ethylbarbituric acid (cyclobarbital),
cyclorphan, cyprenorphine,
7-chloro-5-(2-chlorophenyl)-1H-1,4-benzodiazepin-2(3H)-one
(delorazepam), desomorphine, dextromoramide,
(+)-(1-benzyl-3-dimethylamino-2-methyl-1-phenylpropyl)propionate
(dextropropoxyphen), dezocine, diampromide, diamorphone,
7-chloro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
(diazepam), 4,5a-epoxy-3-methoxy-17-methyl-6a-morphinanol
(dihydrocodeine), 4,5.alpha.-epoxy-17-methyl-3,6a-morphinandiol
(dihydromorphine), dimenoxadol, dimepheptanol, dimethylthiambutene,
dioxaphetyl butyrate, dipipanone,
(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chro-
men-1-ol (dronabinol), eptazocine,
8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
(estazolam), ethoheptazine, ethylmethylthiambutene, ethyl
[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepine-3-ca-
rboxylate](ethyl loflazepate),
4,5.alpha.-epoxy-3-ethoxy-17-methyl-7-morphinen-6.alpha.-ol
(ethylmorphine), etonitazene,
4,5.alpha.-epoxy-7.alpha.-(1-hydroxy-1-methylbutyl)-6-methoxy-17-methyl-6-
,14-endo-etheno-morphinan-3-ol (etorphine),
N-ethyl-3-phenyl-8,9,10-trinorbornan-2-ylamine(fencamfamine),
7-[2-(.alpha.-methyl-phenethylamino)ethyl]-theophylline)
(fenethylline), 3-(.alpha.-methylphenethylamino)propionitrile
(fenproporex), N-(1-phenethyl-4-piperidyl)propionanilide
(fentanyl),
7-chloro-5-(2-fluorophenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one
(fludiazepam),
5-(2-fluorophenyl)-1-methyl-7-nitro-1H-1,4-benzodiazepin-2(3H)-one
(flunitrazepam),
7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin--
2(3H)-one (flurazepam),
7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-2(3H)-one
(halazepam),
10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro[1,3]oxazolyl[3,2-d][1,-
4]benzodiazepin-6(5H)-one (haloxazolam), heroin,
4,5.alpha.-epoxy-3-methoxy-17-methyl-6-morphinanone (hydrocodone),
4,5.alpha.-epoxy-3-hydroxy-17-methyl-6-morphinanone
(hydromorphone), hydroxypethidine, isomethadone, hydroxymethyl
morphinane,
11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]oxazino[3,2-d][1,-
4]benzodiazepine-4,7(6H)-dione (ketazolam),
1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidyl]-1-propanone
(ketobemidone), (3S,6S)-6-dimethylamino-4,4-diphenylheptan-3-yl
acetate(levacetylmethadol (LAAM)),
(-)-6-dimethyl-amino-4,4-diphenol-3-heptanone (levomethadone),
(-)-17-methyl-3-morphinanol (levorphanol), levophenacylmorphane,
lofentanil,
6-(2-chlorophenyl)-2-(4-methyl-1-piperazinylmethylene)-8-nitro-2H-imidazo-
[1,2-a][1,4]-benzodiazepin-[(4H)-one (loprazolam),
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one
(lorazepamy,
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1H-1,4-benzodiazepin-2(3H)-
-one (lormetazepam),
5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol
(mazindol),
7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine
(medazepam),
N-(3-chloropropyl)-.alpha.-methylphenethylamine(mefenorex),
meperidine, 2-methyl-2-propyltrimethylene dicarbamate
(meprobamate), meptazinol, metazocine, methylmorphine,
N,.alpha.-dimethylphenethylamine (methamphetamine),
(.+-.)-6-dimethylamino-4,4-diphenyl-3-heptanone (methadone),
2-methyl-3-o-tolyl-4(3H)-quinazolinone (methaqualone),
methyl[2-phenyl-2-(2-piperidyl)acetate](methylphenidate),
5-ethyl-1-methyl-5-phenylbarbituric acid (methylphenobarbital),
3,3-diethyl-5-methyl-2,4-piperidinedione (methyprylon), metopon,
8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
(midazolam), 2-(benzhydrylsulfinyl)-acetamide (modafinil),
4,5.alpha.-epoxy-17-methyl-7-morphinan-3,6.alpha.-diol (morphine),
myrophine,
(.+-.)-trans-3-(1,1-dimethylheptyl)-7,8,10,10.alpha.-tetrahydro-1-hydroxy-
-6,6-dimethyl-6H-dibenzo[-b,d]pyran-9(6.alpha.H)-one (nabilone),
nalbuphine, nalorphine, narceine, nicomorphine,
1-methyl-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
(nimetazepam), 7-nitro-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
(nitrazepam), 7-chloro-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
(nordazepam), norlevorphanol,
6-dimethylamino-4,4-diphenyl-3-hexanone (normethadone),
normorphine, norpipanone, the exudation for the plants belonging to
the species Papaver somniferum (opium),
7-chloro-3-hydroxy-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
(oxazepam),
(cis-trans)-10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo[3,2-
-d](1,4]benzodiazepin-6-(5H)-one (oxazolam),
4,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-6-morphinanone
(oxycodone), oxymorphone, plants and parts of plants belonging to
the species Papaver somniferum (including the subspecies
setigerum), papaveretum, 2-imino-5-phenyl-4-oxazolidinone
(pernoline),
1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3--
benzazocin-8-ol (pentazocine), 5-ethyl-5-(1-methylbutyl)-barbituric
acid (pentobarbital), ethyl(1-methyl-4-phenyl-4-piperidine
carboxylate) (pethidine), phenadoxone, phenomorphan, phenazocine,
phenoperidine, piminodine, pholcodine, 3-methyl-2-phenylmorpholine
(phenmetrazine), 5-ethyl-5-phenylbarbituric acid (phenobarbital),
.alpha.,.alpha.-dimethylphenethylamine(phentermine),
7-chloro-5-phenyl-1-(2-propynyl)-1H-1,4-benzodiazepin-2(3H)-one
(pinazepam), .alpha.-(2-piperidyl)benzhydryl alcohol (pipradrol),
1'-(3-cyano-3,3-diphenylpropyl)[1,4'-bipiperidine]-4'-carboxamide(piritra-
mide),
7-chloro-1-(cyclopropylmethyl)-5-phenyl-1H-1,4-benzodiazepin-2(3H)--
one (prazepam), profadol, proheptazine, promedol, properidine,
propoxyphene,
N-(1-methyl-2-piperidinoethyl)-N-(2-pyridyl)propionamide, methyl
{3-[4-methoxycarbonyl-4-(N-phenylpropanamido)piperidino]propanoate-
}(remifentanil), 5-sec-butyl-5-ethylbarbituric acid
(secbutabarbital), 5-allyl-5-(1-methylbutyl)-barbituric acid
(secobarbital),
N-{4-methoxymethyl-1-[2-(2-thienyl)ethyl]-4-piperidyl}-propionanilide
(sufentanil),
7-chloro-2-hydroxy-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
(temazepam),
7-chloro-5-(1-cyclohexenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one
(tetrazepam),
ethyl(2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate)(tilidine(cis
and trans)), tramadol,
8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzod-
iazepine (triazolam), 5-(1-methylbutyl)-5-vinylbarbituric acid
(vinylbital),
(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
(1R,2R,4S)-2-(dimethylamino)methyl-4-(p-fluorobenzyloxy)-1-(m-methoxyphen-
yl)cyclohexanol,
(1R,2R)-3-(2-dimethylamino-methylcyclohexyl)phenol,
(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol,
(2R,3R)-1-dimethylamino-3(3-methoxyphenyl)-2-methyl-pentan-3-ol,
(1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexan-1,3-di-
ol, preferably as a racemate,
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl
2-(4-isobutyl-phenyl)-propionate,
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl
2-(6-methoxy-naphthalen-2-yl)-propionate,
3-(2-dimethylamino-methyl-cyclohex-1-enyl)-phenyl
2-(4-isobutyl-phenyl)-propionate,
3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl
2-(6-methoxy-naphthalen-2-yl)-propionate,
(RR-SS)-2-acetoxy-4-trifluoromethyl-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2-hydroxy-4-trifluoromethyl-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-4-chloro-2-hydroxy-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2-hydroxy-4-methyl-benzoic acid
3-(2-dimethylamino-methyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2-hydroxy-4-methoxy-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2-hydroxy-5-nitro-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2',4'-difluoro-3-hydroxy-biphenyl-4-carboxylic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester and
corresponding stereoisomeric compounds, the corresponding
derivatives thereof in each case, in particular amides, esters or
ethers, and the physiologically acceptable compounds thereof in
each case, in particular the salts and solvates thereof,
particularly preferably hydrochlorides.
[0017] The dosage form according to the invention is in particular
suitable for preventing abuse of an opioid active ingredient
selected from the group comprising oxycodone, hydromorphone,
morphine, tramadol and the physiologically acceptable derivatives
or compounds thereof, preferably the salts and solvates thereof,
preferably the hydrochlorides thereof.
[0018] The dosage form according to the invention is furthermore in
particular suitable for preventing abuse of an opioid active
ingredient selected from the group comprising
(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
(1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3--
diol, (1R,2R)-3-(2-dimethylaminoethyl-cyclohexyl)-phenol, the
physiologically acceptable salts thereof, preferably
hydrochlorides, physiologically acceptable enantiomers,
stereoisomers, diastereomers and racemates and the physiologically
acceptable derivatives thereof, preferably ethers, esters or
amides.
[0019] These compounds and processes for the production thereof are
described in EP-A-693475 or EP-A-780369. The corresponding
descriptions are hereby introduced as a reference and are deemed to
be part of the disclosure.
[0020] In order to achieve the necessary breaking strength of the
dosage form according to the invention, at least one synthetic or
natural polymer (C) is used which has a breaking strength, measured
using the method disclosed in the present application, of at least
500 N. At least one polymer selected from the group comprising
polyalkylene oxides, preferably polymethylene oxide, polyethylene
oxide, polypropylene oxide; polyethylene, polypropylene, polyvinyl
chloride, polycarbonate, polystyrene, polyacrylate, copolymers
thereof, and mixtures of at least two of the stated polymers is
preferably used for this purpose. High molecular weight
thermoplastic polyalkylene oxides are preferred. High molecular
weight polyethylene oxides with a molecular weight of at least 0.5
million, preferably of at least 1 million up to 15 million,
determined by rheological measurements, are particularly preferred.
These polymers have a viscosity at 25.degree. C. of 4500 to 17600
cP, measured on a 5 wt. % aqueous solution using a model RVF
Brookfield viscosimeter (spindle no. 2/rotational speed 2 rpm), of
400 to 4000 cP, measured on a 2 wt. % aqueous solution using the
stated viscosimeter (spindle no. 1 or 3/rotational speed 10 rpm) or
of 1650 to 10000 cP, measured on a 1 wt. % aqueous solution using
the stated viscosimeter (spindle no. 2/rotational speed 2 rpm).
[0021] The polymers are preferably used in powder form. They may be
soluble in water.
[0022] In order to achieve the necessary breaking strength of the
dosage form according to the invention, it is furthermore possible
additionally to use at least one natural or synthetic wax (D) with
a breaking strength, measured using the method disclosed in the
present application, of at least 500 N. Waxes with a softening
point of at least 60.degree. C. are preferred. Carnauba wax and
beeswax are particularly preferred. Carnauba wax is very
particularly preferred. Carnauba wax is a natural wax which is
obtained from the leaves of the carnauba palm and has a softening
point of at least 80.degree. C. When the wax component is
additionally used, it is used together with at least one polymer
(C) in quantities such that the dosage form has a breaking strength
of at least 500 N.
[0023] Component (C) is preferably used in an amount of 35 to 99.9
wt. %, particularly preferably of at least 50 wt. %, very
particularly preferably of at least 60 wt. %, relative to the total
weight of the dosage form.
[0024] Auxiliary substances (B) which may be used are those known
auxiliary substances which are conventional for the formulation of
solid dosage forms. These are preferably plasticisers, such as
polyethylene glycol, auxiliary substances which influence active
ingredient release, preferably hydrophobic or hydrophilic,
preferably hydrophilic polymers, very particularly preferably
hydroxypropylcellulose, and/or antioxidants. Suitable antioxidants
are ascorbic acid, butylhydroxyanisole, butylhydroxytoluene, salts
of ascorbic acid, monothioglycerol, phosphorous acid, vitamin C,
vitamin E and the derivatives thereof, sodium bisulfite,
particularly preferably butylhydroxytoluene (BHT) or
butylhydroxyanisole (BHA) and .alpha.-tocopherol.
[0025] The antioxidant is preferably used in quantities of 0.01 to
10 wt. %, preferably of 0.03 to 5 wt. %, relative to the total
weight of the dosage form.
[0026] The dosage forms according to the invention are
distinguished in that, due their hardness, they cannot be
pulverised, for example by grinding in a mortar and pestle. This
virtually rules out oral or parenteral, in particular intravenous
or nasal abuse. However, in order to prevent any possible abuse of
the dosage form according to the invention, the dosage forms
according to the invention may, in a preferred embodiment, contain
further agents which complicate or prevent abuse as auxiliary
substances (B).
[0027] The abuse-proofed dosage form according to the invention,
which comprises, apart from one or more active ingredients with
abuse potential, at least one hardening polymer (C) and optionally
at least one wax (D), may accordingly also comprise at least one of
the following components (a)-(e) as auxiliary substances (B):
[0028] (a) at least one substance which irritates the nasal
passages and/or pharynx, [0029] (b) at least one
viscosity-increasing agent, which, with the assistance of a
necessary minimum quantity of an aqueous liquid, forms a gel with
the extract obtained from the dosage form, which gel preferably
remains visually distinguishable when introduced into a further
quantity of an aqueous liquid, [0030] (c) at least one antagonist
for each of the active ingredients with abuse potential, [0031] (d)
at least one emetic, [0032] (e) at least one dye as an aversive
agent, [0033] (f) at least one bitter substance.
[0034] Components (a) to (f) are additionally each individually
suitable for abuse-proofing the dosage form according to the
invention. Accordingly, component (a) is preferably suitable for
proofing the dosage form against nasal, oral and/or parenteral,
preferably intravenous, abuse, component (b) is preferably suitable
for proofing against parenteral, particularly preferably
intravenous and/or nasal abuse, component (c) is preferably
suitable for proofing against nasal and/or parenteral, particularly
preferably intravenous, abuse, component (d) is preferably suitable
for proofing against parenteral, particularly preferably
intravenous, and/or oral and/or nasal abuse, component (e) is
suitable as a visual deterrent against oral or parenteral abuse and
component (f) is suitable for proofing against oral or nasal abuse.
Combined use according to the invention of at least one of the
above-stated components makes it possible still more effectively to
prevent abuse of dosage forms according to the invention.
[0035] In one embodiment, the dosage form according to the
invention may also comprise two or more of components (a)-(f) in a
combination, preferably (a), (b) and optionally (c) and/or (f)
and/or (e) or (a), (b) and optionally (d) and/or (f) and/or
(e).
[0036] In another embodiment, the dosage form according to the
invention may comprise all of components (a)-(f).
[0037] If the dosage form according to the invention comprises
component (a) to counter abuse, substances which irritate the nasal
passages and/or pharynx which may be considered according to the
invention are any substances which, when administered via the nasal
passages and/or pharynx, bring about a physical reaction which is
either so unpleasant for the abuser that he/she does not wish to or
cannot continue administration, for example burning, or
physiologically counteracts taking of the corresponding active
ingredient, for example due to increased nasal secretion or
sneezing. These substances which conventionally irritate the nasal
passages and/or pharynx may also bring about a very unpleasant
sensation or even unbearable pain when administered parenterally,
in particular intravenously, such that the abuser does not wish to
or cannot continue taking the substance.
[0038] Particularly suitable substances which irritate the nasal
passages and/or pharynx are those which cause burning, itching, an
urge to sneeze, increased formation of secretions or a combination
of at least two of these stimuli. Appropriate substances and the
quantities thereof which are conventionally to be used are known
per se to the person skilled or may be identified by simple
preliminary testing.
[0039] The substance which irritates the nasal passages and/or
pharynx of component (a) is preferably based on one or more
constituents or one or more plant parts of at least one hot
substance drug.
[0040] Corresponding hot substance drugs are known per se to the
person skilled in the art and are described, for example, in
"Pharmazeutische Biologie--Drogen und ihre Inhaltsstoffe" by Prof.
Dr. Hildebert Wagner, 2nd., revised edition, Gustav Fischer Verlag,
Stuttgart-N.Y., 1982, pages 82 et seq. The corresponding
description is hereby introduced as a reference and is deemed to be
part of the disclosure.
[0041] A dosage unit is taken to mean a separate or separable
administration unit, such as for example a tablet or a capsule.
[0042] One or more constituents of at least one hot substance drug
selected from the group consisting of Allii sativi bulbus (garlic),
Asari rhizoma cum herba (Asarum root and leaves), Calami rhizoma
(calamus root), Capsici fructus (capsicum), Capsici fructus acer
(cayenne pepper), Curcumae longae rhizoma (turmeric root), Curcumae
xanthorrhizae rhizoma (Javanese turmeric root), Galangae rhizoma
(galangal root), Myristicae semen (nutmeg), Piperis nigri fructus
(pepper), Sinapis albae semen (white mustard seed), Sinapis nigri
semen (black mustard seed), Zedoariae rhizoma (zedoary root) and
Zingiberis rhizoma (ginger root), particularly preferably from the
group consisting of Capsici fructus (capsicum), Capsici fructus
acer (cayenne pepper) and Piperis nigri fructus (pepper) may
preferably be added as component (a) to the dosage form according
to the invention.
[0043] The constituents of the hot substance drugs preferably
comprise o-methoxy(methyl)phenol compounds, acid amide compounds,
mustard oils or sulfide compounds or compounds derived
therefrom.
[0044] Particularly preferably, at least one constituent of the hot
substance drugs is selected from the group consisting of
myristicin, elemicin, isoeugenol, .alpha.-asarone, safrole,
gingerols, xanthorrhizol, capsaicinoids, preferably capsaicin,
capsaicin derivatives, such as N-vanillyl-9E-octadecenamide,
dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, norcapsaicin
and nomorcapsaicin, piperine, preferably trans-piperine,
glucosinolates, preferably based on non-volatile mustard oils,
particularly preferably based on p-hydroxybenzyl mustard oil,
methylmercapto mustard oil or methylsulfonyl mustard oil, and
compounds derived from these constituents.
[0045] The dosage form according to the invention may preferably
contain the plant parts of the corresponding hot substance drugs in
a quantity of 0.01 to 30 wt. %, particularly preferably of 0.1 to
0.5 wt. %, in each case relative to the total weight of the dosage
unit.
[0046] If one or more constituents of corresponding hot substance
drugs are used, the quantity thereof in a dosage unit according to
the invention preferably amounts to 0.001 to 0.005 wt. %, relative
to the total weight of the dosage unit.
[0047] Another option for preventing abuse of the dosage form
according to the invention consists in adding at least one
viscosity-increasing agent as a further abuse-preventing component
(b) to the dosage form, which, with the assistance of a necessary
minimum quantity of an aqueous liquid, forms a gel with the extract
obtained from the dosage form, which gel is virtually impossible to
administer safely and preferably remains visually distinguishable
when introduced into a further quantity of an aqueous liquid.
[0048] For the purposes of the present invention, visually
distinguishable means that the active ingredient-containing gel
formed with the assistance of a necessary minimum quantity of
aqueous liquid, when introduced, preferably with the assistance of
a hypodermic needle, into a further quantity of aqueous liquid at
37.degree. C., remains substantially insoluble and cohesive and
cannot straightforwardly be dispersed in such a manner that it can
safely be administered parenterally, in particular intravenously.
The material preferably remains visually distinguishable for at
least one minute, preferably for at least 10 minutes.
[0049] The increased viscosity of the extract makes it more
difficult or even impossible for it to be passed through a needle
or injected. If the gel remains visually distinguishable, this
means that the gel obtained on introduction into a further quantity
of aqueous liquid, for example by injection into blood, initially
remains in the form of a largely cohesive thread, which, while it
may indeed be broken up into smaller fragments, cannot be dispersed
or even dissolved in such a manner that it can safely be
administered parenterally, in particular intravenously. In
combination with at least one optionally present component (a) to
(e), this additionally leads to unpleasant burning, vomiting, bad
flavour and/or visual deterrence.
[0050] Intravenous administration of such a gel would most probably
result in obstruction of blood vessels, associated with serious
harm to the health of the abuser.
[0051] In order to verify whether a viscosity-increasing agent is
suitable as component (b) for use in the dosage form according to
the invention, the active ingredient is mixed with the
viscosity-increasing agent and suspended in 10 ml of water at a
temperature of 25.degree. C. If this results in the formation of a
gel which fulfils the above-stated conditions, the corresponding
viscosity-increasing agent is suitable for preventing or averting
abuse of the dosage forms according to the invention.
[0052] If component (b) is added to the dosage form according to
the invention, one or more viscosity-increasing agents are used
which are selected from the group comprising microcrystalline
cellulose with 11 wt. % carboxymethylcellulose sodium (Avicel.RTM.
RC 591), carboxymethylcellulose sodium (Blanose.RTM., CMC-Na
C300P.RTM., Frimulsion BLC-5.RTM., Tylose C300 P.RTM.), polyacrylic
acid (Carbopol.RTM. 980 NF, Carbopol.RTM. 981), locust bean flour
(Cesagum.RTM. LA-200, Cesagum.RTM. LID/150, Cesagum.RTM. LN-1),
pectins, preferably from citrus fruits or apples (Cesapectin.RTM.
HM Medium Rapid Set), waxy maize starch (C*Gel 04201.RTM.), sodium
alginate (Frimulsion ALG (E401).RTM.), guar flour (Frimulsion
BM.RTM., Polygum 26/1-75.RTM.), iota carrageen (Frimulsion
D021.RTM.), karaya gum, gellan gum (Kelcogel F.RTM., Kelcogel
LT100.RTM.), galactomannan (Meyprogat 150.RTM.), tara bean flour
(Polygum 43/1.RTM.), propylene glycol alginate (Protanal-Ester
SD-LB.RTM.), sodium hyaluronate, tragacanth, tara gum (Vidogum SP
200.RTM.), fermented polysaccharide welan gum (K1A96), xanthan gum
(Xantural 180.RTM.). Xanthans are particularly preferred. The names
stated in brackets are the trade names by which the materials are
known commercially. In general, a quantity of 0.1 to 20 wt. %,
particularly preferably of 0.1 to 15 wt. % of the stated
viscosity-increasing agent(s) is sufficient to fulfil the
above-stated conditions.
[0053] The component (b) viscosity-increasing agents, where
provided, are preferably present in the dosage form according to
the invention in quantities of .gtoreq.5 mg per dosage unit, i.e.
per administration unit.
[0054] In a particularly preferred embodiment of the present
invention, the viscosity-increasing agents used as component (b)
are those which, on extraction from the dosage form with the
necessary minimum quantity of aqueous liquid, form a gel which
encloses air bubbles. The resultant gels are distinguished by a
turbid appearance, which provides the potential abuser with an
additional optical warning and discourages him/her from
administering the gel parenterally.
[0055] Component (C) may also optionally serves as an additional
viscosity-increasing agent which, with the assistance of a minimum
necessary quantity of an aqueous liquid, forms a gel.
[0056] It is also possible to formulate the viscosity-increasing
agent and the other constituents in the dosage form according to
the invention in a mutually spatially separated arrangement.
[0057] In order to discourage and prevent abuse, the dosage form
according to the invention may furthermore comprise component (c),
namely one or more antagonists for the active ingredient or active
ingredients with abuse potential, wherein the antagonists are
preferably spatially separated from the remaining constituents of
the invention dosage according to the form and, when correctly
used, do not exert any effect.
[0058] Suitable antagonists for preventing abuse of the active
ingredients are known per se to the person skilled in the art and
may be present in the dosage form according to the invention as
such or in the form of corresponding derivatives, in particular
esters or ethers, or in each case in the form of corresponding
physiologically acceptable compounds, in particular in the form of
the salts or solvates thereof.
[0059] If the active ingredient present in the dosage form is an
opioid, the antagonist used is preferably an antagonist selected
from the group comprising naloxone, naltrexone, nalmefene, nalid,
nalmexone, nalorphine or naluphine, in each case optionally in the
form of a corresponding physiologically acceptable compound, in
particular in the form of a base, a salt or solvate. The
corresponding antagonists, where component (c) is provided, are
preferably used in a quantity of .gtoreq.1 mg, particularly
preferably in a quantity of 3 to 100 mg, very particularly
preferably in a quantity of 5 to 50 mg per dosage form, i.e. per
administration unit.
[0060] If the dosage form according to the invention comprises a
stimulant as active ingredient, the antagonist is preferably a
neuroleptic, preferably at least one compound selected from the
group consisting of haloperidol, promethazine, fluphenazine,
perphenazine, levomepromazine, thioridazine, perazine,
chlorpromazine, chlorprothixine, zuclopentixol, flupentixol,
prothipendyl, zotepine, benperidol, pipamperone, melperone and
bromperidol.
[0061] The dosage form according to the invention preferably
comprises these antagonists in a conventional therapeutic dose
known to the person skilled in the art, particularly preferably in
a quantity of twice to four times the conventional dose per
administration unit.
[0062] If the combination to discourage and prevent abuse of the
dosage form according to the invention comprises component (d), it
may comprise at least one emetic, which is preferably present in a
spatially separated arrangement from the other components of the
dosage form according to the invention and, when correctly used, is
intended not to exert its effect in the body.
[0063] Suitable emetics for preventing abuse of an active
ingredient are known per se to the person skilled in the art and
may be present in the dosage form according to the invention as
such or in the form of corresponding derivatives, in particular
esters or ethers, or in each case in the form of corresponding
physiologically acceptable compounds, in particular in the form of
the salts or solvates thereof.
[0064] An emetic based on one or more constituents of ipecacuanha
(ipecac) root, preferably based on the constituent emetine may
preferably be considered in the dosage form according to the
invention, as are, for example, described in "Pharmazeutische
Biologie--Drogen und ihre Inhaltsstoffe" by Prof. Dr. Hildebert
Wagner, 2nd, revised edition, Gustav Fischer Verlag, Stuttgart,
N.Y., 1982. The corresponding literature description is hereby
introduced as a reference and is deemed to be part of the
disclosure.
[0065] The dosage form according to the invention may preferably
comprise the emetic emetine as component (d), preferably in a
quantity of .gtoreq.3 mg, particularly preferably of .gtoreq.10 mg
and very particularly preferably in a quantity of .gtoreq.20 mg per
dosage form, i.e. administration unit.
[0066] Apomorphine may likewise preferably be used as an emetic in
the abuse-proofing according to the invention, preferably in a
quantity of preferably .gtoreq.3 mg, particularly preferably of
.gtoreq.5 mg and very particularly preferably of .gtoreq.7 mg per
administration unit.
[0067] If the dosage form according to the invention contains
component (e) as a further abuse-preventing auxiliary substance,
the use of a such a dye brings about an intense coloration of a
corresponding aqueous solution, in particular when the attempt is
made to extract the active ingredient for parenteral, preferably
intravenous administration, which coloration may act as a deterrent
to the potential abuser. Oral abuse, which conventionally begins by
means of aqueous extraction of the active ingredient, may also be
prevented by this coloration. Suitable dyes and the quantities
required for the necessary deterrence may be found in WO 03/015531,
wherein the corresponding disclosure should be deemed to be part of
the present disclosure and is hereby introduced as a reference.
[0068] If the dosage form according to the invention contains
component (f) as a further abuse-preventing auxiliary substance,
this addition of at least one bitter substance and the consequent
impairment of the flavour of the dosage form additionally prevents
oral and/or nasal abuse.
[0069] Suitable bitter substances and the quantities effective for
use may be found in US-2003/0064099 A1, the corresponding
disclosure of which should be deemed to be the disclosure of the
present application and is hereby introduced as a reference.
Suitable bitter substances are preferably aromatic oils, preferably
peppermint oil, eucalyptus oil, bitter almond oil, menthol, fruit
aroma substances, preferably aroma substances from lemons, oranges,
limes, grapefruit or mixtures thereof, and/or denatonium benzoate
(Bitrex.RTM.). Denatonium benzoate is particularly preferred.
[0070] The solid dosage form according to the invention is suitable
to be taken orally, vaginally or rectally, preferably orally. The
dosage form is preferably not in film form.
[0071] The dosage form according to the invention may assume
multiparticulate form, preferably in the form of microtablets,
microcapsules, micropellets, granules, spheroids, beads or pellets,
optionally packaged in capsules or pressed into tablets, preferably
for oral administration. The multiparticulate forms preferably have
a size or size distribution in the range from 0.1 to 3 mm,
particularly preferably in the range from 0.5 to 2 mm. Depending on
the desired dosage form, conventional auxiliary substances (B) are
optionally also used for the formulation of the dosage form.
[0072] The solid, abuse-proofed dosage form according to the
invention is preferably produced without using an extruder by
mixing components (A), (B), (C) and optionally (D) and optionally
at least one of the optionally present further abuse-preventing
components (a)-(f) or, if necessary, by separate mixing with the
addition of component (C) and optionally component (D), and,
optionally after granulation, shaping the resultant mixture or
mixtures by application of force to yield the dosage form with
preceding or simultaneous exposure to heat.
[0073] Heating and application of force for the production of the
dosage form proceed without using an extruder.
[0074] Mixing of components (A), (B), (C) and optionally (D) and of
the optionally present further components (a)-(f) and optionally of
components (C) and the optionally present component (D) proceeds
optionally in each case in a mixer known to the person skilled in
the art. The mixer may, for example, be a roll mixer, shaking
mixer, shear mixer or compulsory mixer.
[0075] The resultant mixture is preferably shaped directly by
application of force to yield the dosage form according to the
invention with preceding or simultaneous exposure to heat. The
mixture may, for example, be formed into tablets by direct
tabletting. In direct tabletting with simultaneous exposure to
heat, the tabletting tool, i.e. bottom punch, top punch and die are
briefly heated at least to the softening temperature of the polymer
component (C) and pressed together. In direct tabletting with
preceding exposure to heat, the material to be pressed is heated
immediately prior to tabletting at least to the softening
temperature of component (C) and then pressed with the tabletting
tool.
[0076] The resultant mixture of components (A), (B), (C) and
optionally (D) and the optionally present components (a) to (f) or
the mixture of at least one of these components (a) to (f) with
component (C) may also first be granulated and then be shaped by
application of force with preceding or simultaneous exposure to
heat to yield the dosage form according to the invention.
[0077] When force is applied, it is applied until the dosage form
has achieved a breaking hardness of at least 500 N.
[0078] Granulation may be performed in known granulators by wet
granulation or melt granulation.
[0079] Each of the above-mentioned process steps, in particular the
heating steps and simultaneous or subsequent application of force
for production of the dosage form according to the invention
proceeds without using an extruder.
[0080] In a further preferred embodiment, the dosage form according
to the invention assumes the form of a tablet, a capsule or is in
the form of an oral osmotic therapeutic system (OROS), preferably
if at least one further abuse-preventing component (a)-(f) is also
present.
[0081] If components (c) and/or (d) and/or (f) are present in the
dosage form according to the invention, care must be taken to
ensure that they are formulated in such a manner or are present in
such a low dose that, when correctly administered, said components
are able to bring about virtually no effect which impairs the
patient or the efficacy of the active ingredient.
[0082] If the dosage form according to the invention contains
component (d) and/or (f), the dosage must be selected such that,
when correctly orally administered, no negative effect is caused.
If, however, the intended dosage of the dosage form is exceeded in
the event of abuse, nausea or an inclination to vomit or a bad
flavour are produced. The particular quantity of component (d)
and/or (f) which can still be tolerated by the patient in the event
of correct oral administration may be determined by the person
skilled in the art by simple preliminary testing.
[0083] If, however, irrespective of the fact that the dosage form
according to the invention is virtually impossible to pulverise,
the dosage form containing the components (c) and/or (d) and/or (f)
is provided with protection, these components should preferably be
used at a dosage which is sufficiently high that, when abusively
administered, they bring about an intense negative effect on the
abuser. This is preferably achieved by spatial separation of at
least the active ingredient or active ingredients from components
(c) and/or (d) and/or (f), wherein the active ingredient or active
ingredients is/are present in at least one subunit (X) and
components (c) and/or (d) and/or (f) is/are present in at least one
subunit (Y), and wherein, when the dosage form is correctly
administered, components (c), (d) and (f) do not exert their effect
on taking and/or in the body and the remaining components of the
formulation, in particular component (C) and optionally (D), are
identical.
[0084] If the dosage form according to the invention comprises at
least 2 of components (c) and (d) or (f), these may each be present
in the same or different subunits (Y). Preferably, when present,
all the components (c) and (d) and (f) are present in one and the
same subunit (Y).
[0085] For the purposes of the present invention, subunits are
solid formulations, which in each case, apart from conventional
auxiliary substances known to the person skilled in the art,
contain the active ingredient(s), at least one polymer (C) and the
optionally present component (D) and optionally at least one of the
optionally present components (a) and/or (b) and/or (e) or in each
case at least one polymer (C) and optionally (D) and the
antagonist(s) and/or emetic(s) and/or component (e) and/or
component (f) and optionally at least one of the optionally present
components (a) and/or (b). Care must here be taken to ensure that
each of the subunits is formulated in accordance with the
above-stated process.
[0086] One substantial advantage of the separated formulation of
active ingredients from components (c) or (d) or (f) in subunits
(X) and (Y) of the dosage form according to the invention is that,
when correctly administered, components (c) and/or (d) and/or (f)
are hardly released on taking and/or in the body or are released in
such small quantities that they exert no effect which impairs the
patient or therapeutic success or, on passing through the patient's
body, they are only liberated in locations where they cannot be
sufficiently absorbed to be effective. When the dosage form is
correctly administered, preferably hardly any of components (c)
and/or (d) and/or (f) is released into the patient's body or they
go unnoticed by the patient.
[0087] The person skilled in the art will understand that the
above-stated conditions may vary as a function of the particular
components (c), (d) and/or (f) used and of the formulation of the
subunits or the dosage form. The optimum formulation for the
particular dosage form may be determined by simple preliminary
testing. What is vital is that each subunit contains the polymer
(C) and optionally component (D) and has been formulated in the
above-stated manner.
[0088] Should, contrary to expectations, the abuser succeed in
comminuting such a dosage form according to the invention, which
comprises components (c) and/or (e) and/or (d) and/or (f) in
subunits (Y), for the purpose of abusing the active ingredient and
obtain a powder which is extracted with a suitable extracting
agent, not only the active ingredient but also the particular
component (c) and/or (e) and/or (f) and/or (d) will be obtained in
a form in which it cannot readily be separated from the active
ingredient, such that when the dosage form which has been tampered
with is administered, in particular by oral and/or parenteral
administration, it will exert its effect on taking and/or in the
body combined with an additional negative effect on the abuser
corresponding to component (c) and/or (d) and/or (f) or, when the
attempt is made to extract the active ingredient, the coloration
will act as a deterrent and so prevent abuse of the dosage
form.
[0089] A dosage form according to the invention, in which the
active ingredient or active ingredients is/are spatially separated
from components (c), (d) and/or (e), preferably by formulation in
different subunits, may be formulated in many different ways,
wherein the corresponding subunits may each be present in the
dosage form according to the invention in any desired spatial
arrangement relative to one another, provided that the above-stated
conditions for the release of components (c) and/or (d) are
fulfilled.
[0090] The person skilled in the art will understand that
component(s) (a) and/or (b) which are optionally also present may
preferably be formulated in the dosage form according to the
invention both in the particular subunits (X) and (Y) and in the
form of independent subunits corresponding to subunits (X) and (Y),
provided that neither the abuse-proofing nor the active ingredient
release in the event of correct administration is impaired by the
nature of the formulation and the polymer (C) and optionally (D) is
included in the formulation and formulation is carried out in
accordance with the above-stated process in order to achieve the
necessary hardness.
[0091] In a preferred embodiment of the dosage form according to
the invention, subunits (X) and (Y) are present in multiparticulate
form, wherein microtablets, microcapsules, micropellets, granules,
spheroids, beads or pellets are preferred and the same form, i.e.
shape, is selected for both subunit (X) and subunit (Y), such that
it is not possible to separate subunits (X) from (Y) by mechanical
selection. The multiparticulate forms are preferably of a size in
the range from 0.1 to 3 mm, preferably of 0.5 to 2 mm.
[0092] The subunits (X) and (Y) in multiparticulate form may also
preferably be packaged in a capsule or be pressed into a tablet,
wherein the final formulation in each case proceeds in such a
manner that the subunits (X) and (Y) are also retained in the
resultant dosage form.
[0093] The multiparticulate subunits (X) and (Y) of identical shape
should also not be visually distinguishable from one another so
that the abuser cannot separate them from one another by simple
sorting. This may, for example, be achieved by the application of
identical coatings which, apart from this disguising function, may
also incorporate further functions, such as, for example,
controlled release of one or more active ingredients or provision
of a finish resistant to gastric juices on the particular
subunits.
[0094] The multiparticulate subunits may also be formulated as an
oral dosage form as a slurry or suspension in pharmaceutically safe
suspending media.
[0095] In a further preferred embodiment of the present invention,
subunits (X) and (Y) are in each case arranged in layers relative
to one another.
[0096] The layered subunits (X) and (Y) are preferably arranged for
this purpose vertically or horizontally relative to one another in
the dosage form according to the invention, wherein in each case
one or more layered subunits (X) and one or more layered subunits
(Y) may be present in the dosage form, such that, apart from the
preferred layer sequences (X)-(Y) or (X)-(Y)-(X), any desired other
layer sequences may be considered, optionally in combination with
layers containing components (a) and/or (b).
[0097] Another preferred dosage form according to the invention is
one in which subunit (Y) forms a core which is completely enclosed
by subunit (X), wherein a separation layer (Z) may be present
between said layers. Such a structure is preferably also suitable
for the above-stated multiparticulate forms, wherein both subunits
(X) and (Y) and an optionally present separation layer (Z), which
must satisfy the hardness requirement according to the invention,
are formulated in one and the same multiparticulate form. In a
further preferred embodiment of the dosage form according to the
invention, the subunit (X) forms a core, which is enclosed by
subunit (Y), wherein the latter comprises at least one channel
which leads from the core to the surface of the dosage form.
[0098] The dosage form according to the invention may comprise,
between one layer of the subunit (X) and one layer of the subunit
(Y), in each case one or more, preferably one, optionally swellable
separation layer (Z) which serves to separate subunit (X) spatially
from (Y).
[0099] If the dosage form according to the invention comprises the
layered subunits (X) and (Y) and an optionally present separation
layer (Z) in an at least partially vertical or horizontal
arrangement, the dosage form preferably takes the form of a tablet,
a coextrudate or a laminate.
[0100] In one particularly preferred embodiment, the entirety of
the free surface of subunit (Y) and optionally at least part of the
free surface of subunit(s) (X) and optionally at least part of the
free surface of the optionally present separation layer(s) (Z) may
be coated with at least one barrier layer (Z') which prevents
release of component (c) and/or (e) and/or (d) and/or (f). The
barrier layer (Z') must also fulfil the hardness conditions
according to the invention.
[0101] Another particularly preferred embodiment of the dosage form
according to the invention comprises a vertical or horizontal
arrangement of the layers of subunits (X) and (Y) and at least one
push layer (p) arranged therebetween, and optionally a separation
layer (Z), in which dosage form the entirety of the free surface of
layer structure consisting of subunits (X) and (Y), the push layer
and the optionally present separation layer (Z) is provided with a
semipermeable coating (E), which is permeable to a release medium,
i.e. conventionally a physiological liquid, but substantially
impermeable to the active ingredient and to component (c) and/or
(d) and/or (f), and wherein this coating (E) comprises at least one
opening for release of the active ingredient in the area of subunit
(X).
[0102] A corresponding dosage form is known to the person skilled
in the art, for example under the name oral osmotic therapeutic
system (OROS), as are suitable materials and methods for the
production thereof, inter alia from U.S. Pat. No. 4,612,008, U.S.
Pat. No. 4,765,989 and U.S. Pat. No. 4,783,337. The corresponding
descriptions are hereby introduced as a reference and are deemed to
be part of the disclosure.
[0103] In a further preferred embodiment, the subunit (X) of the
dosage form according to the invention is in the form of a tablet,
the edge face of which and optionally one of the two main faces is
covered with a barrier layer (Z') containing component (c) and/or
(d) and/or (f).
[0104] The person skilled in the art will understand that the
auxiliary substances of the subunit(s) (X) or (Y) and of the
optionally present separation layer(s) (Z) and/or of the barrier
layer(s) (Z') used in formulating the dosage form according to the
invention will vary as a function of the arrangement thereof in the
dosage form according to the invention, the mode of administration
and as a function of the particular active ingredient of the
optionally present components (a) and/or (b) and/or (e) and of
component (c) and/or (d) and/or (f). The materials which have the
requisite properties are in each case known per se to the person
skilled in the art.
[0105] If release of component (c) and/or (d) and/or (f) from
subunit (Y) of the dosage form according to the invention is
prevented with the assistance of a cover, preferably a barrier
layer, the subunit may consist of conventional materials known to
the person skilled in the art, providing that it contains at least
one polymer (C) and optionally (D) to fulfil the hardness condition
of the dosage form according to the invention.
[0106] If a corresponding barrier layer (Z') is not provided to
prevent release of component (c) and/or (d) and/or (f), the
materials of the subunits should be selected such that release of
the particular component (c) and/or (d) from subunit (Y) is
virtually ruled out. The materials which are stated below to be
suitable for production of the barrier layer may preferably be used
for this purpose.
[0107] Preferred materials are those which are selected from the
group comprising alkylcelluloses, hydroxyalkylcelluloses, glucans,
scleroglucans, mannans, xanthans, copolymers of
poly[bis(p-carboxyphenoxy)propane and sebacic acid, preferably in a
molar ratio of 20:80 (commercially available under the name
Polifeprosan 20.RTM.), carboxymethylcelluloses, cellulose ethers,
cellulose esters, nitrocelluloses, polymers based on (meth)acrylic
acid and the esters thereof, polyamides, polycarbonates,
polyalkylenes, polyalkylene glycols, polyalkylene oxides,
polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers,
polyvinyl esters, halogenated polyvinyls, polyglycolides,
polysiloxanes and polyurethanes and the copolymers thereof.
[0108] Particularly suitable materials may be selected from the
group comprising methylcellulose, ethylcellulose,
hydroxypropylcellulose, hydroxypropylmethylcellulose,
hydroxybutylmethylcellulose, cellulose acetate, cellulose
propionate (of low, medium or high molecular weight), cellulose
acetate propionate, cellulose acetate butyrate, cellulose acetate
phthalate, carboxymethylcellulose, cellulose triacetate, sodium
cellulose sulfate, polymethyl methacrylate, polyethyl methacrylate,
polybutyl methacrylate, polyisobutyl methacrylate, polyhexyl
methacrylate, polyisodecyl methacrylate, polylauryl methacrylate,
polyphenyl methacrylate, polymethyl acrylate, polyisopropyl
acrylate, polyisobutyl acrylate, polyoctadecyl acrylate,
polyethylene, low density polyethylene, high density polyethylene,
polypropylene, polyethylene glycol, polyethylene oxide,
polyethylene terephthalate, polyvinyl alcohol, polyvinyl isobutyl
ether, polyvinyl acetate and polyvinyl chloride.
[0109] Particularly suitable copolymers may be selected from the
group comprising copolymers of butyl methacrylate and isobutyl
methacrylate, copolymers of methyl vinyl ether and maleic acid with
high molecular weight, copolymers of methyl vinyl ether and maleic
acid monoethyl ester, copolymers of methyl vinyl ether and maleic
anhydride and copolymers of vinyl alcohol and vinyl acetate.
[0110] Further materials which are particularly suitable for
formulating the barrier layer are starch-filled polycaprolactone
(WO98/20073), aliphatic polyesteramides (DE 19 753 534 A1, DE 19
800 698 A1, EP 0 820 698 A1), aliphatic and aromatic polyester
urethanes (DE 19822979), polyhydroxyalkanoates, in particular
polyhydroxybutyrates, polyhydroxyvalerates, casein (DE 4 309 528),
polylactides and copolylactides (EP 0 980 894 A1). The
corresponding descriptions are hereby introduced as a reference and
are deemed to be part of the disclosure.
[0111] The above-stated materials may optionally be blended with
further conventional auxiliary substances known to the person
skilled in the art, preferably selected from the group comprising
glyceryl monostearate, semi-synthetic triglyceride derivatives,
semi-synthetic glycerides, hydrogenated castor oil, glyceryl
palmitostearate, glyceryl behenate, polyvinylpyrrolidone, gelatine,
magnesium stearate, stearic acid, sodium stearate, talcum, sodium
benzoate, boric acid and colloidal silica, fatty acids, substituted
triglycerides, glycerides, polyoxyalkylene glycols and the
derivatives thereof.
[0112] If the dosage form according to the invention comprises a
separation layer (Z'), said layer, like the uncovered subunit (Y),
may preferably consist of the above-stated materials described for
the barrier layer. The person skilled in the art will understand
that release of the active ingredient or of component (c) and/or
(d) from the particular subunit may be controlled by the thickness
of the separation layer.
[0113] The dosage form according to the invention exhibits
controlled release of the active ingredient. It is preferably
suitable for twice daily administration to patients.
[0114] The dosage form according to the invention may comprise one
or more active ingredients at least partially in controlled release
form, wherein controlled release may be achieved with the
assistance of conventional materials and methods known to the
person skilled in the art, for example by embedding the active
ingredient in a controlled release matrix or by the application of
one or more controlled release coatings. Active ingredient release
must, however, be controlled such that the above-stated conditions
are fulfilled in each case, for example that, in the event of
correct administration of the dosage form, the active ingredient or
active ingredients are virtually completely released before the
optionally present component (c) and/or (d) can exert an impairing
effect. Addition of materials effecting controlled release must
moreover not impair the necessary hardness.
[0115] Controlled release from the dosage form according to the
invention is preferably achieved by embedding the active ingredient
in a matrix. The auxiliary substances acting as matrix materials
control active ingredient release. Matrix materials may, for
example, be hydrophilic, gel-forming materials, from which active
ingredient release proceeds mainly by diffusion, or hydrophobic
materials, from which active ingredient release proceeds mainly by
diffusion from the pores in the matrix.
[0116] Physiologically acceptable, hydrophobic materials which are
known to the person skilled in the art may be used as matrix
materials. Polymers, particularly preferably cellulose ethers,
cellulose esters and/or acrylic resins are preferably used as
hydrophilic matrix materials. Ethylcellulose,
hydroxypropylmethylcellulose, hydroxypropylcellulose,
hydroxymethylcellulose, poly(meth)acrylic acid and/or the
derivatives thereof, such as the salts, amides or esters thereof
are very particularly preferably used as matrix materials.
[0117] Matrix materials prepared from hydrophobic materials, such
as hydrophobic polymers, waxes, fats, long-chain fatty acids, fatty
alcohols or corresponding esters or ethers or mixtures thereof are
also preferred. Mono- or diglycerides of C12-C30 fatty acids and/or
C12-C30 fatty alcohols and/or waxes or mixtures thereof are
particularly preferably used as hydrophobic materials.
[0118] It is also possible to use mixtures of the above-stated
hydrophilic and hydrophobic materials as matrix materials.
Component (C) and the optionally present component (D), which serve
to achieve the breaking strength of at least 500 N which is
necessary according to the invention may furthermore also
optionally serve as additional matrix materials.
[0119] If the dosage form according to the invention is intended
for oral administration, it may also preferably comprise a coating
which is resistant to gastric juices and dissolves as a function of
the pH value of the release environment. By means of this coating,
it is possible to ensure that the dosage form according to the
invention passes through the stomach undissolved and the active
ingredient is only released in the intestines. The coating which is
resistant to gastric juices preferably dissolves at a pH value of
between 5 and 7.5.
[0120] Corresponding materials and methods for the controlled
release of active ingredients and for the application of coatings
which are resistant to gastric juices are known to the person
skilled in the art, for example from "Coated Pharmaceutical Dosage
Forms--Fundamentals, Manufacturing Techniques, Biopharmaceutical
Aspects, Test Methods and Raw Materials" by Kurt H. Bauer, K.
Lehmann, Hermann P. Osterwald, Rothgang, Gerhart, 1st edition,
1998, Medpharm Scientific Publishers. The corresponding literature
description is hereby introduced as a reference and is deemed to be
part of the disclosure.
Method for Determining Breaking Strength
[0121] In order to verify whether a polymer may be used as
component (C) or (D), the polymer is pressed to form a tablet with
a diameter of 10 mm and a height of 5 mm using a force of 150 N at
a temperature which at least corresponds to the softening point of
the polymer and is determined with the assistance of a DSC diagram
of the polymer. Using tablets produced in this manner, breaking
strength is determined with the apparatus described below in
accordance with the method for determining the breaking strength of
tablets published in the European Pharmacopoeia 1997, page 143-144,
method no. 2.9.8. The apparatus used for the measurement is a
"Zwick Z 2.5" materials tester, Fmax=2.5 kN with a maximum draw of
1150 mm, which should be set up with 1 column and 1 spindle, a
clearance behind of 100 mm and a test speed adjustable between 0.1
and 800 mm/min together with testControl software. Measurement is
performed using a pressure piston with screw-in inserts and a
cylinder (diam. 10 mm), a force transducer, Fmax. 1 kN, diameter=8
mm, class 0.5 from 10 N, class 1 from 2 N to ISO 7500-1, with
manufacturer's test certificate M to DIN 55350-18 (Zwick gross
force Fmax=1.45 kN) (all apparatus from Zwick GmbH & Co. KG,
Ulm, Germany) with order no. BTC-FR 2.5 TH. D09 for the tester,
order no. BTC-LC 0050N. P01 for the force transducer, order no. BO
70000 S06 for the centring device.
[0122] FIG. 1 shows the measurement of the breaking strength of a
tablet, in particular the tablet (4) adjustment device (6) used for
this purpose before and during the measurement. To this end, the
tablet (4) is held between the upper pressure plate (1) and the
lower pressure plate (3) of the force application apparatus (not
shown) with the assistance of two 2-part clamping devices, which
are in each case firmly fastened (not shown) with the upper and
lower pressure plate once the spacing (5) necessary for
accommodating and centring the tablet to be measured has been
established. The spacing (5) may be established by moving the
2-part clamping devices horizontally outwards or inwards in each
case on the pressure plate on which they are mounted.
[0123] The tablets deemed to be resistant to breaking under a
specific load include not only those which have not broken but also
those which may have suffered plastic deformation under the action
of the force.
[0124] In the case of the dosage forms according to the invention,
breaking strength is determined in accordance with the stated
method, dosage forms other than tablets also being tested.
[0125] The following Examples illustrate the invention purely by
way of example and without restricting the general concept of the
invention.
EXAMPLES
[0126] Tramadol hydrochloride was used as the active ingredient in
a series of Examples. Tramadol hydrochloride was used, despite
tramadol not being an active ingredient which conventionally has
abuse potential, because it is not governed by German narcotics
legislation, so simplifying the experimental work. Tramadol is
moreover a member of the opioid class with excellent water
solubility.
Example 1
[0127] TABLE-US-00001 Complete Components Per tablet batch Tramadol
hydrochloride 100 mg 100 g Polyethylene oxide, NF, 200 mg 200 g MW
7 000 000 (Polyox WSR 303, Dow Chemicals) Total weight 300 mg 300
g
[0128] Tramadol hydrochloride and polyethylene oxide powder were
mixed in a free-fall mixer. A tabletting tool with top punch,
bottom punch and die for tablets with a diameter of 10 mm and a
radius of curvature of 8 mm was heated to 80.degree. C. in a
heating cabinet. 300 mg portions of the powder mixture were pressed
with the heated tool, wherein pressure was maintained for at least
15 seconds by clamping the tabletting tool in a vice.
[0129] The breaking strength of the tablets was determined with the
stated apparatus in accordance with the stated method. The tablets
did not break when exposed to a force of 500 N. The tablet could
not be comminuted using a hammer, nor with the assistance of a
mortar and pestle.
[0130] In vitro release of the active ingredient from the
preparation was determined in a paddle stirrer apparatus in
accordance with Pharm. Eur. The temperature of the release medium
was 37.degree. C. and the rotational speed of the stirrer 75
min.sup.-1. At the beginning of the investigation, each tablet was
placed in a 600 ml portion of artificial gastric juice, pH 1.2.
After 30 minutes, the pH value was increased to 2.3 by addition of
alkali solution, after a further 90 minutes to pH 6.5 and after a
further 60 minutes to pH 7.2. The released quantity of active
ingredient present in the dissolution medium at each point in time
was determined by spectrophotometry. TABLE-US-00002 Time Released
quantity 30 min 15% 240 min 52% 480 min 80% 720 min 99%
Example 2
[0131] 300 mg portions of the powder mixture from Example 1 were
heated to 80.degree. C. and in placed in the die of the tabletting
tool. Pressing was then performed. The tablet exhibits the same
properties such as the tablet in Example 1.
Example 3
[0132] TABLE-US-00003 Raw material Per tablet Complete batch
Tramadol hydrochloride 50 mg 100 g Polyethylene oxide, NF, 100 mg
200 g MW 7 000 000 (Polyox WSR 303, Dow Chemicals) Total weight 150
mg 300 g
[0133] Tramadol hydrochloride and the above-stated components were
mixed in a free-fall mixer. A tabletting tool with top punch,
bottom punch and die for tablets with a diameter of 7 mm was heated
to 80.degree. C. in a heating cabinet. 150 mg portions of the
powder mixture were pressed with the heated tool, wherein pressure
was maintained for at least 15 seconds by clamping the tabletting
tool in a vice.
[0134] The breaking strength of the tablets was determined with the
stated apparatus in accordance with the stated method. The tablets
did not break when exposed to a force of 500 N.
[0135] In vitro release of the active ingredient was determined as
in Example 1 and was: TABLE-US-00004 Time Released quantity 30 min
15% 240 min 62% 480 min 88% 720 min 99%
Example 4
[0136] TABLE-US-00005 Complete Raw material Per tablet batch
Tramadol hydrochloride 100 mg 100 g Polyethylene oxide, NF, 180 mg
180 g MW 7 000 000 (Polyox WSR 303, Dow Chemicals) Xanthan, NF 20
mg 20 g Total weight 300 mg 300 g
[0137] Tramadol hydrochloride, xanthan and polyethylene oxide were
mixed in a free-fall mixer. A tabletting tool with top punch,
bottom punch and die for tablets with a diameter of 10 mm and a
radius of curvature of 8 mm was heated to 80.degree. C. in a
heating cabinet. 300 mg portions of the powder mixture were pressed
with the heated tool, wherein pressure was maintained for at least
15 seconds by clamping the tabletting tool in a vice.
[0138] The breaking strength of the tablets was determined with the
stated apparatus in accordance with the stated method. The tablets
did not break when exposed to a force of 500 N. The tablets did
suffer a little plastic deformation.
[0139] In vitro release of the active ingredient was determined as
in Example 1 and was: TABLE-US-00006 Time Released quantity 30 min
14% 240 min 54% 480 min 81% 720 min 99%
[0140] The tablets could be cut up with a knife into pieces of an
edge length of as small as approx. 2 mm. No further comminution
proceeding as far as pulverisation was possible. When the pieces
are combined with water, a highly viscous gel is formed. Only with
great difficulty could the gel be pressed through a 0.9 mm
injection cannula. When the gel was injected into water, the gel
did not spontaneously mix with water, but remained visually
distinguishable.
Example 5
[0141] TABLE-US-00007 Complete Raw material Per tablet batch
Tramadol hydrochloride 50 mg 100 g Polyethylene oxide, NF, 90 mg
180 g MW 7 000 000 (Polyox WSR 303, Dow Chemicals) Xanthan, NF 10
mg 20 g Total weight 300 mg 300 g
[0142] Tramadol hydrochloride, xanthan and polyethylene oxide were
mixed in a free-fall mixer. A tabletting tool with a top punch,
bottom punch and die for oblong tablets 10 mm in length and 5 mm in
width was heated to 90.degree. C. in a heating cabinet. 150 mg
portions of the powder mixture were pressed with the heated tool,
wherein pressure was maintained for at least 15 seconds by clamping
the tabletting tool in a vice.
[0143] The breaking strength of the tablets was determined with the
stated apparatus in accordance with the stated method. The tablets
did not break when exposed to a force of 500 N. The tablets did
suffer a little plastic deformation.
[0144] In vitro release of the active ingredient was determined as
in Example 1 and was: TABLE-US-00008 Time Released quantity 30 min
22% 120 min 50% 240 min 80% 360 min 90% 480 min 99%
[0145] The tablets could be cut up with a knife into pieces of an
edge length of as small as approx. 2 mm, but could not be
pulverised. When the pieces are combined with water, a highly
viscous gel is formed. Only with great difficulty could the gel be
pressed through a 0.9 mm injection cannula. When the gel was
injected into water, the gel did not spontaneously mix with water,
but remained visually distinguishable.
Example 6
[0146] A tablet with the following composition was produced as
described in Example 1: TABLE-US-00009 Components Per tablet Per
batch Oxycodone hydrochloride 20.0 mg 0.240 g Xanthan, NF 20.0 mg
0.240 g Polyethylene oxide, NF, 110.0 mg 1.320 g MW 7 000 000
(Polyox WSR 303, Dow Chemicals) Total weight 150.0 mg 1.800 g
[0147] Release of the active ingredient was determined as
follows:
[0148] In vitro release of the active ingredient from the
preparation was determined in a paddle stirrer apparatus in
accordance with Pharm. Eur. The temperature of the release medium
was 37.degree. C. and the rotational speed 75 rpm. The phosphate
buffer, pH 6.8, described in USP served as the release medium. The
quantity of active ingredient present in the solvent at the
particular time of testing was determined by spectrophotometry.
TABLE-US-00010 Time Mean 0 min 0% 30 min 17% 240 min 61% 480 min
90% 720 min 101.1%
[0149] The breaking strength of the tablets was determined with the
stated apparatus in accordance with the stated method. The tablets
did not break when exposed to a force of 500 N.
[0150] The tablets could be cut up with a knife into pieces of an
edge length of as small as approx. 2 mm, but could not be
pulverised. When the pieces are combined with water, a highly
viscous gel is formed. Only with great difficulty could the gel be
pressed through a 0.9 mm injection cannula. When the gel was
injected into water, the gel did not spontaneously mix with water,
but remained visually distinguishable.
Example 7
[0151] TABLE-US-00011 Components Per tablet Per batch Tramadol HCl
100.0 mg 2.0 g Polyethylene oxide, NF, 221.0 mg 4.42 g MW 7 000 000
(Polyox WSR 303, Dow Chemicals) Hydroxypropylmethylcellulose 20.0
mg 0.4 g (Metholose 90 SH 100 000 cP from ShinEtsu)
Butylhydroxytoluene (BHT) 0.2 mg 0.004 g Total weight 341.2 mg
6.824 g
[0152] The stated quantity of BHT was dissolved in ethanol (96%),
such that a 7.7% (mass/mass) ethanolic solution was obtained. This
was mixed with the polyethylene oxide and then dried for 12 h at
40.degree. C.
[0153] All the further components were added to this dried mixture
and mixed for 15 min in a free-fall mixer.
[0154] The tablets were produced using the same method as stated in
Example 1. Round punches (diameter 10 mm) with a radius of
curvature of 8 mm were used.
[0155] The breaking strength of the tablets was determined in
accordance with the stated method. The tablets did not break when
exposed to a force of 500 N. The tablets could not be comminuted
either with a hammer or with the assistance of a mortar and
pestle.
[0156] In vitro release of the active ingredient from the dosage
form was determined in accordance with the details in Example 1 in
order to determine release. TABLE-US-00012 Released quantity of
active Time ingredient 30 min 17% 240 min 59% 480 min 86% 720 min
98%
Example 8
[0157] TABLE-US-00013 Components Per tablet Per batch Tramadol HCl
100.0 mg 2.0 g Polyethylene oxide, NF, 221.0 mg 4.42 g MW 7 000 000
(Polyox WSR 303, Dow Chemicals) Hydroxypropylmethylcellulose 20.0
mg 0.4 g (Metholose 90 SH 100 000 cP from ShinEtsu) Total weight
341.0 mg 6.82 g
[0158] The individual components were mixed for 15 min in a
free-fall mixer. The tablets were produced in accordance with
Example 1 using a hot tabletting tool. Round punches (diameter 10
mm) with a radius of curvature of 8 mm were used.
[0159] The breaking strength of the tablets was determined in
accordance with the stated method. The tablets did not break when
exposed to a force of 500 N. The tablets could not be comminuted
either with a hammer or with the assistance of a mortar and
pestle.
[0160] In vitro release of the active ingredient from the
preparation was determined as stated in Example 1. TABLE-US-00014
Released quantity of active Time ingredient 30 min 16% 240 min 57%
480 min 84% 720 min 96%
* * * * *